Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Continues to Increase Awareness of Novel Psychedelic Drug Candidates

  • Pharmaceutical company Tryp Therapeutics is preparing for clinical trials evaluating synthetic formulations of psilocybin to treat medical conditions with underpinning neurological causes
  • The clinical trials planned are being conducted in partnership with research teams at the University of Florida and the University of Michigan
  • Tryp executives have been meeting with investors at select conferences recently to increase awareness, including the just-completed Sept. 21 presentation at Oppenheimer’s Fall Healthcare Life Sciences & MedTech Summit
  • The company expects to initiate Phase 2a trials to begin before the end of the year for treating certain eating disorders, with Phase 2b trials to follow next year

Novel pharmaceutical company Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) continues to garner attention for its development of psilocybin as potential treatments for medical conditions with largely unmet needs, presenting an overview of its business and ongoing clinical trials for its two trademarked drug candidates most recently at the Oppenheimer Fall Healthcare Summit.  

Tryp is nearing the launch of a Phase 2a clinical trial that aims to establish the value of its psychedelic drug candidate, TRP-8802, in treating chronic and severe eating disorders such as Prader-Willi Syndrome (PWS), hypothalamic obesity disorder resulting from the removal of a brain tumor, and binge eating dysfunction.

The company also plans to execute Phase 2b clinical trials for its proprietary psychedelic candidate TRP-8803 to evaluate its ability to penetrate the natural blood-brain barrier and effectively alleviate pain and addiction concerns, including targets for phantom limb pain and fibromyalgia.

Oppenheimer’s Fall Healthcare Life Sciences & MedTech Summit featured companies’ presentations and one-on-one meetings by invitation only through a virtual platform online. Tryp joined other select public companies in the sector for a presentation that paired investors with management teams to discuss key programs in detail, delivering its address on Sept. 21 (https://ibn.fm/30YVm).

The management team also presented an overview of the company the prior week at the H.C. Wainwright 23rd Annual Global Investment Conference and at the Canaccord Genuity Virtual Growth Conference last month. 

“I am excited to showcase the transformative work that Tryp Therapeutics is doing in collaboration with our academic research partners such as the University of Michigan and the University of Florida,” Tryp Chairman and CEO Greg McKee stated in July (https://ibn.fm/P8zw8). “The next six months represent an important stage in development for us as we initiate multiple Phase 2a clinical trials and move closer to providing additional treatment options for the millions of patients suffering from a variety of chronic pain diseases and eating disorders.”

Tryp’s product development moves beyond the initial interests in testing psychedelics for treating solely mental health issues such as depression, anxiety, addiction, and PTSD, combining supervised administration of the drug with psychotherapy in response to select medical conditions in which specific neurological maladies play a causal role. 

Tryp also is distinguishing itself by developing a novel method of administration for its TRP-8803 candidate to make the experience better for patients, leading to a provisional patent to protect the unique features of the proprietary formulation. 

The company’s drug products are manufactured in the United States as part of an exclusive supply chain for its active ingredients that assures Tryp will have sufficient quantities to complete its clinical trials and establish eventual commercialization.

Tryp expects Phase 2a trials for the eating disorders and for phantom limb pain to begin before the end of the year (https://ibn.fm/finBj).

For more information, visit the company’s website at www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF 

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Archives

Select A Month

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050